CERT

Certara, Inc. (CERT) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers Certara, Inc.'s quarterly report on Form 10-Q for the period ended June 30, 2026. Certara is a global leader in biosimulation science, technology, and consulting services, utilizing Model-Informed Drug Development (MIDD) to assist the biopharmaceutical industry. The reporting period is significantly impacted by the divestiture of the company's Regulatory and Medical Writing business, which was sold to Veristat, LLC on May 8, 2026, and is now classified as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Discontinued Operations Impact: The sale of the Regulatory and Medical Writing business resulted in a pre-tax loss of approximately $65.5 million, recorded in discontinued operations. This drove the significant net loss for the quarter and year-to-date, despite stable performance in continuing operations.
• Revenue Growth: Continuing operations revenue increased 1% quarter-over-quarter and 2% year-over-year. Software revenue grew 4% (Q2) and 6% (YTD), while Services revenue declined slightly.
• Expense Increases: General and Administrative (G&A) expenses surged 31% in Q2 and 41% YTD. This was primarily driven by a $13.1 million increase in business acquisition contingent consideration expense and reorganization costs, rather than core operational bloat.
• Stock Repurchases: The company utilized $57.4 million of its $100 million authorized repurchase program in the first six months of 2026, exhausting the authorization. On August 3, 2026, the Board authorized an additional $50 million for repurchases.
• Debt Refinancing: In October 2025, the company refinanced its term loan, reducing the applicable interest rate margin. The effective interest rate for the term loan decreased to 6.45% for the six months ended June 30, 2026, from 7.40% in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management expects continued investment in scientific talent, sales, and R&D, particularly in AI integration. The company maintains a strong liquidity position with $184.1 million in cash and a $100 million undrawn revolving credit facility.
• Key Risks:
  • Regulatory Dependence: Demand is tied to regulatory acceptance of model-informed drug development; changes in FDA or global agency policies could reduce demand.
  • Customer Concentration: While no single customer exceeds 10% of revenue, the company relies on the biopharmaceutical industry's R&D spending levels.
  • Divestiture Integration: Risks related to realizing expected benefits from the sale of the medical writing business and managing transition services.
  • AI and Technology: Potential reputational or legal risks associated with the implementation of AI and machine learning in regulated environments.
• Unusual Items: The contingent consideration expense fluctuation was a major driver of G&A volatility. The company also recorded reorganization expenses related to lease abandonment and entity restructuring.

Investor Verification Checklist

• Discontinued Operations Finality: Verify the final settlement of the $15 million escrow and the potential $35 million earn-out from the Veristat sale to confirm the final loss on disposal.
• Contingent Consideration Volatility: Review the assumptions behind the $7.2 million increase in contingent consideration expense to understand future earnings volatility.
• Software vs. Services Mix: Monitor the trend of declining Services revenue versus growing Software revenue to assess the shift toward a more recurring revenue model.
• Stock Repurchase Execution: Track the utilization of the new $50 million repurchase authorization approved in August 2026.
• Debt Covenants: Confirm continued compliance with the Credit Agreement covenants, particularly given the recent refinancing and leverage ratios.